Journal of Internal Medicine Concepts & Practice >

2024 , Vol. 19 >Issue 05: 303 - 309

DOI: https://doi.org/10.16138/j.1673-6087.2024.05.03

Original article

Study on the correlation between serum MG53 level and coronary artery calcification

  • ZHANG Yu ,
  • ZHA Qing ,
  • YANG Ling ,
  • YE Jiawen ,
  • YANG Ke ,
  • LIU Yan
Expand
  • 1. Department of Cardiology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
    2. Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2024-01-22

  Online published: 2025-01-16

Fold

Abstract

Objective To study the correlation between serum MG53 level and coronary artery calcification (CAC), and the correlation between serum MG53 level and the prognosis of patients with CAC. Methods A total of 195 patients admitted to the Department of Cardiovascular Medicine of Ruijin Hospital， Shanghai Jiao Tong University School of Medicine from 2016 to 2018 due to chest distress and other discomforts were selected. CAC was confirmed by coronary CT angiography (CTA) in all patients. Agatston integral was used to calculate CAC score, and serum MG53 level was detected by enzyme-linked immunosorbent assay. Patients were followed up for 5 years, and the endpoint events were recorded. Patients were grouped according to CAC score and serum MG53 level. Logistic regression was used to analyze the correlation between serum MG53 level and CAC level. Kaplan-Meier curve and COX proportional risk model were used to analyze the effect of serum MG53 level on the prognosis of CAC patients. The R software (4.2.2 version) was used to calculate the best cut-off value of serum MG53 level for predicting end-point events. Results Compared with the low-risk group，the serum MG53 level in the high-risk group was significantly lower [57.717 (28.548，139.965) pg/mL vs 33.553 (13.509，56.952) pg/mL, P<0.001]. Serum MG53 level was independently associated with the severity of CAC (OR=0.984, 95%CI：0.971-0.994, P<0.007). The risk of cardiovascular events was significantly increased in patients with low MG53 levels (OR=0.282, 95%CI：0.160-0.498, P<0.001). The cutoff value of MG53 was calculated as 18.36 pg/mL. Conclusions Serum MG53 level may be related to the degree of CAC and the prognosis of patients，suggesting that serum MG53 level may be a biomarker for predicting CAC and the prognosis of patients.

Key words： Coronary artery calcification; MG53; Coronary artery calcium score; Biomarkers; Prognosis; CT angiography

Cite this article

ZHANG Yu , ZHA Qing , YANG Ling , YE Jiawen , YANG Ke , LIU Yan . Study on the correlation between serum MG53 level and coronary artery calcification[J]. Journal of Internal Medicine Concepts & Practice, 2024 , 19(05) : 303 -309 . DOI: 10.16138/j.1673-6087.2024.05.03

References

[1] Hashmi S, Shah PW, Aherrahrou Z, et al. Beyond the basics: unraveling the complexity of coronary artery calcification[J]. Cells, 2023, 12(24):2822.
[2] Mohan J, Bhatti K, Tawney A, et al. Coronary artery calcification[M/OL]. 2023. https://www.ncbi.nlm.nih.gov/books/NBK519037/.
[3] Ji B, Liu XB. Coronary artery calcification: concepts and clinical applications[J]. Ann Med Surg (Lond), 2024, 86(5):2848-2855.
[4] Song R, Peng W, Zhang Y, et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders[J]. Nature, 2013, 494(7437):375-379.
[5] Jiang W, Liu M, Gu C, et al. The pivotal role of mitsugumin 53 in cardiovascular diseases[J]. Cardiovasc Toxicol, 2021, 21(1):2-11.
[6] Feng H, Shen H, Robeson MJ, et al. MG53 E3 ligase-dead mutant protects diabetic hearts from acute ischemic/reperfusion injury and ameliorates diet-induced cardiometabolic damage[J]. Diabetes, 2022, 71(2):298-314.
[7] Cao CM, Zhang Y, Weisleder N, et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning[J]. Circulation, 2010, 121(23):2565-2574.
[8] Pagliaro P, Penna C. Cardiac postconditioning[J]. Antioxid Redox Signal, 2011, 14(5):777-779.
[9] Han X, Chen D, Liufu N, et al. MG53 protects against sepsis-induced myocardial dysfunction by upregulating peroxisome proliferator-activated receptor-α[J]. Oxid Med Cell Longev, 2020, 2020:7413693.
[10] Xie H, Wang Y, Zhu T, et al. Serum MG53/TRIM72 is associated with the presence and severity of coronary artery disease and acute myocardial infarction[J]. Front Physiol, 2020, 11:617845.
[11] Xie H, Yan Z, Feng S, et al. Prognostic value of circulating MG53 levels in acute myocardial infarction[J]. Front Cardiovasc Med, 2020, 7:596107.
[12] van der Aalst CM, Denissen SJAM, Vonder M, et al. Screening for cardiovascular disease risk using traditional risk factor assessment or coronary artery calcium scoring: the ROBINSCA trial[J]. Eur Heart J Cardiovasc Imaging, 2020, 21(11):1216-1224.
[13] Zhao Y, Qian Y, Sun Z, et al. Role of PI3K in the progression and regression of atherosclerosis[J]. Front Pharmacol, 2021, 12:632378.
[14] Hao N, Zhou Z, Zhang F, et al. Interleukin-29 accelerates vascular calcification via JAK2/STAT3/BMP2 signaling[J]. J Am Heart Assoc, 2023, 12(1):e027222.
[15] Huang H, Feng H, Zhuge D. M1 macrophage activated by notch signal pathway contributed to ventilator-induced lung injury in chronic obstructive pulmonary disease model[J]. J Surg Res, 2019, 244:358-367.
[16] Liu C, Li B, Tang K, et al. Aquaporin 1 alleviates acute kidney injury via PI3K-mediated macrophage M2 polarization[J]. Inflamm Res, 2020, 69(5):509-521.
[17] Kang JH, Kawano T, Murata M, et al. Vascular calcification and cellular signaling pathways as potential therapeutic targets[J]. Life Sci, 2024, 336:122309.
[18] Chen X, Su J, Feng J, et al. TRIM72 contributes to cardiac fibrosis via regulating STAT3/Notch-1 signaling[J]. J Cell Physiol, 2019, 234(10):17749-17756.
[19] Wang Y, Zhou H, Wu J, et al. MG53 alleviates hypoxia/reoxygenation-induced cardiomyocyte injury by succinylation and ubiquitination modification[J]. Clin Exp Hypertens, 2023, 45(1):2271196.
[20] Li Z, Dai R, Chen M, et al. p55γ degrades RIP3 via MG53 to suppress ischaemia-induced myocardial necroptosis and mediates cardioprotection of preconditioning[J]. Cardiovasc Res, 2023, 119(14):2421-2440.
Options
Outlines

/

〈 〉